Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KRISTOPHER PAUL WENTZEL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1427317403
CMS profile
1382370
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$66.73

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $66.73 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Exelixis Inc. $66.73 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KRISTOPHER PAUL WENTZEL

NPI 1427317403 · CMS profile ID 1382370

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427317403?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KRISTOPHER PAUL WENTZEL, NPI 1427317403, CMS profile ID 1382370. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427317403?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). KRISTOPHER PAUL WENTZEL, NPI 1427317403, CMS profile ID 1382370. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427317403?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
KRISTOPHER PAUL WENTZEL, NPI 1427317403, CMS profile ID 1382370, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1427317403?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $66.73 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exelixis Inc. $66.7302/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737174427 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $258.39 4
PY2020 $66.73 1
PY2022 $149.72 1
PY2023 $297.02 7
PY2025 $20.39 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $875,889.16 102
PY2024 Principal investigator $355,489.16 58
PY2023 Principal investigator $200,725.75 71
PY2022 Principal investigator $800,305.94 86
PY2021 Principal investigator $304,624.96 41
PY2020 Principal investigator $177,548.51 34
PY2019 Principal investigator $66,224.87 19

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Exelixis Inc. $12,777.00 12/21/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943765003
Principal investigator 1 Exelixis Inc. $4,152.00 12/21/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943765005
Principal investigator 1 Exelixis Inc. $1,950.00 12/21/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943765007
Principal investigator 1 Exelixis Inc. $861.00 12/14/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764899
Principal investigator 1 Exelixis Inc. $1,170.00 12/14/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764901
Principal investigator 1 Exelixis Inc. $163.44 12/14/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764903
Principal investigator 1 Exelixis Inc. $650.00 12/09/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764855
Principal investigator 1 Exelixis Inc. $390.00 12/09/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764857
Principal investigator 1 Exelixis Inc. $35.39 12/09/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764859
Principal investigator 1 Exelixis Inc. $2,776.00 12/09/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764861
Principal investigator 1 Exelixis Inc. $24,309.00 12/09/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764881
Principal investigator 1 Exelixis Inc. $12,456.00 12/09/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764883
Principal investigator 1 Exelixis Inc. $4,290.00 12/09/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764885
Principal investigator 1 Exelixis Inc. $4,858.00 12/09/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764887
Principal investigator 1 Exelixis Inc. $557,896.50 11/23/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764797
Principal investigator 1 Exelixis Inc. $8,886.00 10/17/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764437
Principal investigator 1 Exelixis Inc. $374.00 10/17/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764439
Principal investigator 1 Exelixis Inc. $8,304.00 10/17/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764441
Principal investigator 1 Exelixis Inc. $1,950.00 10/17/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943764443
Principal investigator 1 Exelixis Inc. $748.00 09/28/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762979
Principal investigator 1 Exelixis Inc. $503.83 09/28/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762981
Principal investigator 1 Exelixis Inc. $1,755.00 09/16/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762833
Principal investigator 1 Exelixis Inc. $410.00 09/16/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762835
Principal investigator 1 Exelixis Inc. $780.00 09/16/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762837
Principal investigator 1 Exelixis Inc. $92.66 09/16/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762937
Principal investigator 1 Exelixis Inc. $374.00 08/24/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762685
Principal investigator 1 Exelixis Inc. $92.66 08/24/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762687
Principal investigator 1 Exelixis Inc. $8,304.00 08/03/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762501
Principal investigator 1 Exelixis Inc. $780.00 08/03/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762503
Principal investigator 1 Exelixis Inc. $251.31 08/03/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762505
Principal investigator 1 Exelixis Inc. $5,850.00 08/03/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762579
Principal investigator 1 Exelixis Inc. $4,443.00 08/03/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762581
Principal investigator 1 Exelixis Inc. $374.00 08/03/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762583
Principal investigator 1 Exelixis Inc. $1,236.00 07/13/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762225
Principal investigator 1 Exelixis Inc. $1,300.00 07/13/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762227
Principal investigator 1 Exelixis Inc. $419.64 07/13/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762229
Principal investigator 1 Exelixis Inc. $374.00 07/06/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762197
Principal investigator 1 Exelixis Inc. $398.11 07/06/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943762199
Principal investigator 1 Exelixis Inc. $460.00 06/20/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760675
Principal investigator 1 Exelixis Inc. $748.00 06/20/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760677
Principal investigator 1 Exelixis Inc. $4,152.00 06/20/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760679
Principal investigator 1 Exelixis Inc. $1,560.00 06/20/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760681
Principal investigator 1 Exelixis Inc. $390.00 06/20/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760683
Principal investigator 1 Exelixis Inc. $780.00 06/20/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760685
Principal investigator 1 Exelixis Inc. $3,056.81 06/20/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760687
Principal investigator 1 Exelixis Inc. $3,470.00 06/20/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760689
Principal investigator 1 Exelixis Inc. $1,950.00 05/11/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760337
Principal investigator 1 Exelixis Inc. $1,170.00 05/11/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760339
Principal investigator 1 Exelixis Inc. $4,550.00 05/11/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760341
Principal investigator 1 Exelixis Inc. $1,092.00 05/11/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760343
Principal investigator 1 Exelixis Inc. $203.11 05/11/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760345
Principal investigator 1 Exelixis Inc. $6,384.00 04/22/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760223
Principal investigator 1 Exelixis Inc. $2,079.00 04/22/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760225
Principal investigator 1 Exelixis Inc. $4,152.00 04/22/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760227
Principal investigator 1 Exelixis Inc. $780.00 04/22/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760229
Principal investigator 1 Exelixis Inc. $1,040.54 04/22/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760231
Principal investigator 1 Exelixis Inc. $6,384.00 04/08/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760117
Principal investigator 1 Exelixis Inc. $4,152.00 04/08/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760119
Principal investigator 1 Exelixis Inc. $390.00 04/08/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943760121
Principal investigator 1 Exelixis Inc. $374.00 03/25/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766867
Principal investigator 1 Exelixis Inc. $707.01 03/23/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943767063
Principal investigator 1 Exelixis Inc. $1,388.00 03/23/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943767065
Principal investigator 1 Exelixis Inc. $18,762.00 03/18/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766969
Principal investigator 1 Exelixis Inc. $780.00 03/18/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766971
Principal investigator 1 Exelixis Inc. $390.64 03/14/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766903
Principal investigator 1 Exelixis Inc. $11,700.00 03/09/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766859
Principal investigator 1 Exelixis Inc. $780.00 03/09/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766861
Principal investigator 1 Exelixis Inc. $8,487.00 03/02/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766791
Principal investigator 1 Exelixis Inc. $964.00 03/02/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766793
Principal investigator 1 Exelixis Inc. $4,152.00 03/02/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766795
Principal investigator 1 Exelixis Inc. $1,170.00 03/02/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766797
Principal investigator 1 Exelixis Inc. $453.04 03/02/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766799
Principal investigator 1 Exelixis Inc. $4,443.00 03/02/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766811
Principal investigator 1 Exelixis Inc. $260.00 03/02/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766813
Principal investigator 1 Exelixis Inc. $1,170.00 03/02/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766815
Principal investigator 1 Exelixis Inc. $1,755.00 03/02/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766823
Principal investigator 1 Exelixis Inc. $374.00 03/02/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766825
Principal investigator 1 Exelixis Inc. $405.61 03/02/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766827
Principal investigator 1 Exelixis Inc. $860.60 02/09/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766375
Principal investigator 1 Exelixis Inc. $4,560.00 02/09/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766377
Principal investigator 1 Exelixis Inc. $4,443.00 02/04/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766187
Principal investigator 1 Exelixis Inc. $734.00 02/04/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766189
Principal investigator 1 Exelixis Inc. $4,152.00 02/04/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766191
Principal investigator 1 Exelixis Inc. $390.00 02/04/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766193
Principal investigator 1 Exelixis Inc. $520.00 02/04/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766259
Principal investigator 1 Exelixis Inc. $453.04 02/04/2022 Non-covered Recipient Entity
Cedars-Sinai Medical Care Foundation
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 943766261